Medtronic (NYSE: MDT) today announced new long-term results from its final report of the SPYRAL HTN-ON MED trial.
Medtronic plc , a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback